Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Blood

Volumn 125, Issue 16, 2015, Pages 2497-2506

  Byrd, John C ^a   Furman, Richard R ^b   Coutre, Steven E ^c   Burger, Jan A ^d   Blum, Kristie A ^a   Coleman, Morton ^b   Wierda, William G ^d   Jones, Jeffrey A ^a   Zhao, Weiqiang ^a   Heerema, Nyla A ^a   Johnson, Amy J ^a   Shaw, Yun ^e   Bilotti, Elizabeth ^e   Zhou, Cathy ^e   James, Danelle F ^e   O'Brien, Susan ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 3A4 INHIBITOR; GROWTH FACTOR; IBRUTINIB; IMMUNOGLOBULIN; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFLUENZA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOMA; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINUSITIS; SKIN PRURITUS; SUBDURAL HEMATOMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHEMICALLY INDUCED; CHROMOSOME DELETION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NEUTROPENIA; PATHOLOGY; RECURRENT DISEASE; REMISSION; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PNEUMONIA; PYRAZOLES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927732048     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-606038     Document Type: Article

References (43)

1. Hallek M, Cheson BD, Catovsky D, et al International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
2. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
3. Lozanski G, Ruppert AS, Heerema NA, et al. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012;53(9):1743-1748.
4. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448-5457.
5. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
6. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
7. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
8. Messina M, Del Giudice I, Khiabanian H, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood. 2014;123(15):2378-2388.
9. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437-443.
10. Hallek M, Fischer K, Fingerle-Rowson G, et al International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
11. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.
12. th American Society of Hematology Annual Meeting and Exposition. December 7-10, 2013. New Orleans, LA.
13. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
14. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
15. Gribben JG, Hosing C, Maloney DG. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S63-S70.
16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
17. O'Brien SG, Guilhot F, Larson RA, et al IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
18. Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am Soc Hematol Educ Program. 2011;2011:104-109.
19. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
20. Ponader S, Chen S-S, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
21. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
22. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009;69(13):5424-5432.
23. Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
24. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-3612.
25. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
26. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
27. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
28. Byrd JC, Brown JR, O'Brien S, et al RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
29. Pharmacyclics, Inc. IMBRUVICA® (ibrutinib) [package insert]. Sunnyvale, CA: Pharmacyclics, Inc., 2015.
30. Cheson BD, Pfistner B, Juweid ME, et al International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
31. Byrd JC, McGrail LH, Hospenthal DR, Howard RS, Dow NA, Diehl LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol. 1999;105(2):445-447.
32. Smith DD, Goldstein L, Cheng M, et al. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. Ann Hematol. 2015;94(2):249-256.
33. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-1817.
34. Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30(14):1647-1655.
35. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623.
36. Stephens DM, Ruppert AS, Jones JA, et al. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del (17p13.1) karyotype at a single center. Leukemia. 2014;28(6):1365-1368.
37. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
38. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
39. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphomas, v3. Available at www.nccn.org. Accessed July 31, 2014.
40. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.
41. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
42. th American Society of Hematology Annual Meeting and Exposition. December 7-10, 2013. New Orleans, LA.
43. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.